Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2019 | 3 |
2020 | 2 |
2021 | 2 |
2024 | 0 |
Search Results
6 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma.
Eur J Cancer. 2021 Apr;147:1-12. doi: 10.1016/j.ejca.2021.01.010. Epub 2021 Feb 15.
Eur J Cancer. 2021.
PMID: 33601293
Free article.
Clinical Trial.
Defining EGFR amplification status for clinical trial inclusion.
French PJ, Eoli M, Sepulveda JM, de Heer I, Kros JM, Walenkamp A, Frenel JS, Franceschi E, Clement PM, Weller M, Ansell P, Looman J, Bain E, Morfouace M, Gorlia T, van den Bent M.
French PJ, et al. Among authors: looman j.
Neuro Oncol. 2019 Oct 9;21(10):1263-1272. doi: 10.1093/neuonc/noz096.
Neuro Oncol. 2019.
PMID: 31125418
Free PMC article.
Item in Clipboard
EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligand.
Hoogstrate Y, Vallentgoed W, Kros JM, de Heer I, de Wit M, Eoli M, Sepulveda JM, Walenkamp AME, Frenel JS, Franceschi E, Clement PM, Weller M, van Royen ME, Ansell P, Looman J, Bain E, Morfouace M, Gorlia T, Golfinopoulos V, van den Bent M, French PJ.
Hoogstrate Y, et al. Among authors: looman j.
Neurooncol Adv. 2019 Dec 9;2(1):vdz051. doi: 10.1093/noajnl/vdz051. eCollection 2020 Jan-Dec.
Neurooncol Adv. 2019.
PMID: 32642719
Free PMC article.
Item in Clipboard
Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma.
Lassman AB, Aldape KD, Ansell PJ, Bain E, Curran WJ, Eoli M, French PJ, Kinoshita M, Looman J, Mehta M, Muragaki Y, Narita Y, Ocampo C, Roberts-Rapp L, Song M, Vogelbaum MA, Walenkamp AME, Wang TJC, Zhang P, van den Bent MJ.
Lassman AB, et al. Among authors: looman j.
J Neurooncol. 2019 Aug;144(1):205-210. doi: 10.1007/s11060-019-03222-y. Epub 2019 Jul 4.
J Neurooncol. 2019.
PMID: 31273577
Free PMC article.
Clinical Trial.
Item in Clipboard
INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma.
Van Den Bent M, Eoli M, Sepulveda JM, Smits M, Walenkamp A, Frenel JS, Franceschi E, Clement PM, Chinot O, De Vos F, Whenham N, Sanghera P, Weller M, Dubbink HJ, French P, Looman J, Dey J, Krause S, Ansell P, Nuyens S, Spruyt M, Brilhante J, Coens C, Gorlia T, Golfinopoulos V.
Van Den Bent M, et al. Among authors: looman j.
Neuro Oncol. 2020 May 15;22(5):684-693. doi: 10.1093/neuonc/noz222.
Neuro Oncol. 2020.
PMID: 31747009
Free PMC article.
Clinical Trial.
Item in Clipboard
Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma.
van den Bent M, Eoli M, Sepulveda JM, Smits M, Walenkamp A, Frenel JS, Franceschi E, Clement PM, Chinot O, de Vos F, Whenham N, Sanghera P, Weller M, Dubbink HJ, French P, Looman J, Dey J, Krause S, Ansell P, Nuyens S, Spruyt M, Brilhante J, Coens C, Gorlia T, Golfinopoulos V.
van den Bent M, et al. Among authors: looman j.
Neuro Oncol. 2021 Aug 2;23(8):1415. doi: 10.1093/neuonc/noaa115.
Neuro Oncol. 2021.
PMID: 32609812
Free PMC article.
No abstract available.
Item in Clipboard
Cite
Cite